切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2019, Vol. 13 ›› Issue (06) : 435 -439. doi: 10.3877/cma.j.issn.1674-0785.2019.06.006

所属专题: 文献

临床研究

中晚期结直肠癌术中腹腔灌注雷替曲塞局部化疗不良反应评估
贾海峰1, 卜延志1,(), 刘艳艳2, 濮娟2, 王万鹏2   
  1. 1. 223400 江苏淮安,南京医科大学康达学院附属涟水县人民医院普外科
    2. 223400 江苏淮安,南京医科大学康达学院附属涟水县人民医院放疗科
  • 收稿日期:2018-12-14 出版日期:2019-03-15
  • 通信作者: 卜延志

Adverse effects of intraoperative infusion of Raltitrexed in patients with advanced colorectal cancer

Haifeng Jia1, Yanzhi Bo1,(), Yanyan Liu2, Juan Pu2, Wanpeng Wang2   

  1. 1. General Surgery Department, Lianshui First People's Hospital, Huaian 223400, China
    2. Radiotherapy Department, Lianshui First People's Hospital, Huaian 223400, China
  • Received:2018-12-14 Published:2019-03-15
  • Corresponding author: Yanzhi Bo
  • About author:
    Corresponding author: Bo Yanzhi, Email:
引用本文:

贾海峰, 卜延志, 刘艳艳, 濮娟, 王万鹏. 中晚期结直肠癌术中腹腔灌注雷替曲塞局部化疗不良反应评估[J/OL]. 中华临床医师杂志(电子版), 2019, 13(06): 435-439.

Haifeng Jia, Yanzhi Bo, Yanyan Liu, Juan Pu, Wanpeng Wang. Adverse effects of intraoperative infusion of Raltitrexed in patients with advanced colorectal cancer[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(06): 435-439.

目的

对中晚期结直肠癌术中腹腔灌注雷替曲塞局部化疗引起的不良反应进行评估。

方法

选取2016年1月至2017年8月在南京医科大学康达学院附属涟水县人民医院治疗的40例中晚期结直肠癌手术的患者,分为观察组与对照组,观察组19例,对照组21例,观察组采用结直肠癌根治性手术+术中腹腔灌注雷替曲塞,对照组采用常规结直肠癌根治性手术,术后2组患者均接受6个疗程化疗及巩固性放疗。采用独立样本t检验比较观察组与对照组血液系统指标、手术时间及住院时间的差异,采用ANOVA方差检验比较手术前后的差异;采用χ2检验比较2组患者术后并发症、骨髓抑制等方面的差异。

结果

观察组患者术后白细胞计数稍增高,而对照组术后白细胞计数稍有下降,但2组间比较差异无统计学意义(P>0.05);2组患者除术后4周的血小板计数稍有增高外,其余术后的血小板计数均较术前稍有降低,2组比较差异均无统计学意义(P>0.05);2组患者术后血红蛋白浓度较术前均有所降低,但2组比较差异均无统计学意义(P>0.05);观察组患者术后肝功能未见异常变化,对照组患者术后肝功能稍有增高,但2组比较差异无统计学意义(P>0.05);2组患者肾功能水平术后较术前均稍有增高,但组间比较差异无统计学意义(P>0.05);2组患者白细胞、血小板、血红蛋白、肝功能、肾功能术前与术后比较差异均无统计学意义(P>0.05)。2组患者手术及住院时间比较差异无统计学意义(P>0.05)。2组患者术后并发症比较差异均无统计学意义(P>0.05)。观察组与对照组患者术后均未出现重度骨髓抑制。

结论

中晚期结直肠癌术中腹腔灌注雷替曲塞化疗是可行且安全的,其操作简单且患者能耐受。

Objective

To evaluate the adverse effects of intraoperative chemotherapy with retetroxacin in patients with advanced colorectal cancer.

Methods

Forty patients with locally advanced colorectal cancer who underwent surgical treatment from January 2016 to August 2017 at Lianshui First People's Hospital Affiliated to Institute of Kangda of Nanjing Medical University were selected and divided into either an observation group (19 cases) or a control group (12 cases). The observation group underwent radical surgery plus intraoperative perfusion of retetroxacin, and the control group underwent radical surgery alone. Both groups of patients received six cycles of chemotherapy and consolidation radiotherapy. Hematological system indexes, operation time, and hospitalization days were compared between the two groups by the independent sample t-test. ANOVA was performed to compare preoperative and postoperative differences. Age, sex, tumor site, postoperative complications, and bone marrow suppression were compared by the χ2 test.

Results

The number of postoperative leukocytes slightly increased in the observation group, and slightly decreased in the control group, but the difference between the two groups was not statistically significant (P>0.05). Except for a slight increase in the number of platelets at 4 weeks after the operation, the number of platelets in the two groups was slightly lower than that before the operation, and the difference between the two groups was not statistically significant (P>0.05). The postoperative levels of hemoglobin in the two groups were lower than those before the operation, but the difference between the two groups was not statistically significant (P>0.05). Postoperative liver function indexes of patients in the observation group showed no abnormal changes, while patients in the control group showed a slight increase in postoperative liver function indexes, but the difference between the two groups was not statistically significant (P>0.05). Renal function indexes of the two groups increased slightly after surgery compared with those before surgery, but the difference between the two groups was not statistically significant (P>0.05). Compared with preoperative values, there was no significant difference in the postoperative values of WBC, platelets, hemoglobin, liver function, or renal function (P>0.05). There was no significant difference in operative time or postoperative complications between the two groups (P>0.05). No severe myelosuppression was observed in either group.

Conclusion

It is feasible and safe to use intraoperative Raltitrexed chemotherapy in patients with advanced colorectal cancer.

表1 2组结直肠癌患者一般临床资料比较(例)
表2 2组结直肠癌患者临床TNM分期比较(例)
表3 2组结直肠癌患者血液系统术前与术后检测指标的比较(±s
组别 例数 白细胞计数(×109/L) F P
术前 术后3 d 术后1周 术后2周 术后4周
观察组 19 7.49±1.54 7.68±1.35 7.59±1.58 7.49±1.43 7.48±1.57 ? ?
对照组 21 7.26±1.98 7.13±2.02 7.20±1.74 7.21±1.63 7.21±1.85 1.200 0.310
t ? 0.401 1.004 0.735 0.575 0.490 ? ?
P ? 0.691 0.322 0.467 0.569 0.627 ? ?
组别 例数 血小板(×109/L) F P
术前 术后3 d 术后1周 术后2周 术后4周 ? ?
观察组 19 184.21±53.39 182.37±52.86 182.95±53.64 183.53±53.39 184.21±42.93 ? ?
对照组 21 179.90±66.81 176.10±63.16 179.71±60.55 179.38±65.61 180.71±61.13 0.163 0.840
t ? 0.224 0.339 0.178 0.218 0.207 ? ?
P ? 0.824 0.737 0.860 0.829 0.837 ? ?
组别 例数 血红蛋白(g/L) F P
术前 术后3 d 术后1周 术后2周 术后4周 ? ?
观察组 19 125.84±8.37 116.16±13.34 108.84±17.15 112.53±14.21 123.89±12.91 ? ?
对照组 21 125.33±13.80 108.71±11.36 104.05±15.36 109.67±14.28 122.90±11.06 0.505 0.679
t ? 0.139 1.905 0.276 0.634 0.55 ? ?
P ? 0.890 0.064 0.357 0.530 0.795 ? ?
组别 例数 丙氨酸氨基转移酶(U/L) F P
术前 术后3 d 术后1周 术后2周 术后4周 ? ?
观察组 19 32.95±10.76 32.95±9.61 33.95±7.61 32.68±9.90 32.16±9.51 ? ?
对照组 21 30.19±10.46 32.81±10.53 33.67±7.29 30.81±9.42 30.57±6.52 0.445 0.674
t ? 0.821 0.043 0.119 0.614 0.621 ? ?
P ? 0.417 0.966 0.906 0.543 0.539 ? ?
组别 例数 天冬氨酸氨基转移酶(U/L) F P
术前 术后3 d 术后1周 术后2周 术后4周 ? ?
观察组 19 26.74±4.34 27.63±4.67 26.11±3.96 26.73±4.24 26.16±4.57 ? ?
对照组 21 25.57±6.22 27.05±5.64 25.81±4.77 25.67±6.13 25.52±5.89 0.155 0.851
t ? 0.680 0.354 0.212 0.613 0.377 ? ?
P ? 0.501 0.725 0.833 0.543 0.708 ? ?
组别 例数 肌酐(mmol/L) F P
术前 术后3 d 术后1周 术后2周 术后4周 ? ?
观察组 19 73.23±12.53 74.66±12.57 73.33±12.51 73.32±12.59 73.23±12.23 ? ?
对照组 21 71.94±16.52 73.14±13.77 72.45±14.10 72.31±15.70 71.98±16.37 0.197 0.713
t ? 0.276 0.15 0.206 0.220 0.272 ? ?
P ? 0.784 0.877 0.838 0.825 0.787 ? ?
表4 2组结直肠癌患者手术时间、住院时间及术后并发症比较
1
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
2
Fujita T. Colorectal cancer [J]. Lancet, 2010, 376(9738): 331; author reply 331-332.
3
Jayne DG, Fook S, Loi C, et al. Peritoneal careinomatosis from colorectal cancer [J]. Br J Surg, 2002, 89(12): 1545-1550.
4
Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases [J]. Cancer Res, 1983, 43(4): 1488-1492.
5
Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapyin advanced gastric cancer. Meta-analysis of randomized trials [J]. Eur J Surg Oncol, 2014, 40(1): 12-26.
6
Xiong HQ, Ajani JA. Treatment of colorectal cancer metastasis: therole of chemotherapy [J]. Cancer and Metastasis Reviews, 2004, 23(1): 145-163.
7
Antonio A, Elena DG, Lucrezia S, et al. Targeting thymidylatesynthase in colorectal cancer: critical re-evaluation and emergingtherapeutic role of raltitrexed [J]. Expert Opin Drug Saf, 2014, 13(1): 113-129.
8
Wilson KS, Malfair Taylor SC. Rahitrexed: optimism and reality [J]. Expert Opin Drug Metab Toxicol, 2009, 5(11): 1447-1454.
9
国家卫生计生委医政医管局,中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2015版) [J/CD]. 中华胃肠外科杂志, 2015, 18(10): 961-973.
10
韩朝阳,曹道俊,李富梅, 等. 进展期胃癌术前氟尿嘧啶腹腔和静脉化疗药代动力学的比较研究 [J]. 中国普通外科杂志, 2001, 10(3): 262-263.
11
郭锰. 进展期胃癌术后腹腔化疗的临床疗效分析 [J]. 中华肿瘤防治杂志, 2011, 18(5): 374-376.
12
Nagao S, Kurosaki A, Iwasa N, et al. Intraperitoneal chemotherapy [J]. Nihon Rinsho, 2012, 70 Suppl 4: 610-616.
13
Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials [J]. Eur J Surg Oncol, 2014, 40(1): 12-26.
14
王雪玮,周海涛,王锡山. 结直肠癌术中腹腔化疗专家意见(2017版) [J/CD]. 中华结直肠疾病电子杂志, 2017, 6(6): 442-446.
15
刘俊宝,张弘纲,邵竹筠, 等. 雷替曲塞三线治疗转移性结直肠癌62例临床观察 [J]. 中华肿瘤防治杂志, 2018, 25(4): 275-281.
16
单留群,刘德林,吴昌德, 等. 雷替曲塞用于胃肠道肿瘤术中腹腔灌注的安全性研究 [J/CD]. 中华临床医师杂志(电子版), 2014, 8(18): 3232-3235.
[1] 宋勇, 李东炫, 王翔, 李锐. 基于数据挖掘法分析3 种超声造影剂不良反应信号[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 890-898.
[2] 季思涵, 唐新宇, 王邦杰, 狄汶洋, 王佳鸣, 查小明, 谢晖, 周文斌, 潘红, 王水. 阿贝西利在激素受体阳性、HER-2 阴性乳腺癌患者中的安全性研究[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 281-286.
[3] 陈桂华, 钟小玲, 谢雨, 王慧, 谢江, 杨涛毅. 合并肝脏疾病特殊健康状态儿童疫苗预防接种及时性临床分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(04): 431-439.
[4] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[5] 袁庆港, 刘理想, 张亮, 周世振, 高波, 丁超, 管文贤. 尿素-肌酐比值(UCR)可预测结直肠癌患者术后的长期预后[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 506-509.
[6] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[7] 何岩, 向文采. 七氟醚与异丙酚联合氯胺酮麻醉在疝修补术中的镇静镇痛效果及安全性[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 566-569.
[8] 宋华传, 季鹏, 姚焕章, 王永帅, 张珅瑜, 宋瑞鹏, 王继洲. 腹腔镜肝切除术联合微波消融治疗多发性结直肠癌肝转移[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(04): 222-226.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[11] 赵泽云, 李建男, 王旻. 中性粒细胞胞外诱捕网在结直肠癌中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 524-528.
[12] 王国强, 张纲, 唐建坡, 张玉国, 杨永江. LINC00839 调节miR-17-5p/WEE1 轴对结直肠癌细胞增殖、凋亡和迁移的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 491-499.
[13] 孙晗, 于冰, 武侠, 周熙朗. 基于循环肿瘤DNA 甲基化的结直肠癌筛查预测模型的构建与验证[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 500-506.
[14] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[15] 王湛, 李文坤, 杨奕, 徐芳, 周敏思, 苏珈仪, 王亚丹, 吴静. 炎症指标在早发性结直肠肿瘤中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 802-810.
阅读次数
全文


摘要